TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03240796

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: minimal invasive surgery and secondary IOL implantation
Description: We decreased the size of the capsulorhexis opening to 1.0-1.5 mm in diameter and moved the location of the capsulorhexis to the peripheral area of the lens instead of the central area. A 0.9 mm phacoemulsification probe was used to remove the lens contents and/or cortical opacities. Secondary IOL implantation: implant the IOL either into the capsule bag or fix at the ciliary sulcus.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: traditional cataract surgery and secondary IOL implantation
Description: traditional cataract surgery: anterior continuous capsulorhexis + irrigation/aspiration + posterior capsulorhexis + anterior vitrectomy (ACCC+ I/A + PCCC + Anti-vit).~Secondary IOL implantation: implant the IOL either into the capsule bag or fix at the ciliary sulcus.
Study: NCT03184987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: Salbutamol is a rescue medication administered via metered-dose inhaler (MDI) which will be used when needed during the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ACQ-7
Description: ACQ-7 will be used for the assessment of control status of asthma.
Study: NCT02605811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: prophylaxis cranial radiotherapy
Description: 2
Study: NCT00969176

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: paracetamol
Description: Intravenous paracetamol administration in neonates, loading dose 20 mg/kg, followed by a Gestational age-dependent maintenance dose of 10-20 mg/kg/24 h, divided in 4 doses (each 6h)
Study: NCT03451344

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated rehabilitation group
Description: Participant in integrated rehabilitation group needs to visit their corresponding social worker and accept illicit drug test every two months. Social worker will help their corresponding client to apply for social benefits accordingly, and provide counseling irregularly if necessary. The integrated rehabilitation group received the standardized community-based rehabilitation described above and simultaneously received a 6-month integrated rehabilitation based on CAREs (Community-based Addiction Rehabilitation Electronic System).CAREs was developed by the department of addiction research in Shanghai Mental Health Center(SMHC), with functions including education, support, psychological intervention and other functions.
Study: NCT00852124

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: VSL#3 or placebo
Description: 1 packet 2 x daily of placebo
Study: NCT01904760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine(4㎍/mL) : 0.5㎍/kg/hr infusion for 1 hour before operation is completed and 0.2-0.7㎍/kg/hr infusion continuously until 6:00am the next day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo
Description: Normal saline 0.9% (guess as 4㎍/mL) : 0.5㎍/kg/hr infusion for 1 hour before operation is completed and 0.2-0.7㎍/kg/hr infusion continuously until 6:00am the next day
Study: NCT03480620

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online Telerehabilitation Platform Access
Description: Participants will have 24/7 access to a standardized set post-discharge exercise videos and self-management instructions across multiple internet connected devices (e.g. computer, tablet, smartphone). Standardized exercises include a flexibility routine that participants learned and performed with a physical therapist while in the pain management program. Self-management instructions are also written versions of concepts learned and practiced with a member of the multidisciplinary team during the pain management program.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Participants are given a DVD of the standardized post-discharge exercise videos and a written copy of the self-management instructions as described in the experimental group.
Study: NCT00324727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Given throug isolated hepatic artery infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: regional chemotherapy
Description: Patients receive the best alternative therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: systemic chemotherapy
Description: Patients receive the best alternative therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hepatic artery embolization
Description: Patients receive the best alternative therapy
Study: NCT04351633

Intervention type: OTHER
Intervention: questionnaire assesment
Description: questionnaire assesment
Study: NCT01026311

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coenzyme q 10
Description: 200 mg of Coenzyme q 10

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 placebo q d during treatment period
Study: NCT01873183

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Goal directed fluid therapy
Study: NCT01960049

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine + iv PCA

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: saline and IV PCA
Study: NCT01529710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myrrh
Description: Subjects will be treated by Mirazid as 600 mg oral (Soft Gelatin Capsules) for 6 consecutive days or 40mg/Kg body weight of Praziquantel as a single oral dose. Subjects will be evaluated for success of treatment at 12 weeks of treatment. Evaluation will be done by examining urine or stool samples for Schistosomiasis including egg counts for the positive cases.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Myrrh
Description: Subjects will be treated by Mirazid as 600 mg oral (Soft Gelatin Capsules) for 6 consecutive days or 40mg/Kg body weight of Praziquantel as a single oral dose. Subjects will be evaluated for success of treatment at 12 weeks of treatment. Evaluation will be done by examining urine or stool samples for Schistosomiasis including egg counts for the positive cases.
Study: NCT01008189

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self- study comparison group
Description: Caregivers, children and adolescents each received three books about coping with grief following the death of a loved one plus a syllabus to guide reading

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Bereavement Program
Description: 12 session groups for caregivers and bereaved children and adolescents plus two individual sessions
Study: NCT02052011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: Subjects will take the extended-release Ranolazine for a total of 4 weeks. Subjects will take 500 mg twice daily for the first week and then 1000 mg twice daily for remaining period (Dosing will be adjusted with concomitant use of diltiazem, verapamil, erythromycin, simvastatin or metformin).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00750581

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indomethacin
Description: Infants randomized to Escalating Dose group will receive indomethacin (0.2 mg/kg/dose) at 12 hr intervals for 2 doses, followed by indomethacin (0.3 mg/kg/dose) at 12 hr interval for 2 doses, then Indomethacin (0.4 mg/kg/dose) at 12 hr interval for 2 doses, increased to indomethacin (0.5 mg/kg/dose) at 12 hour interval for 2 doses and finally indomethacin 0.6 mg/kg/dose at 12 hourly interval for 2 doses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Indomethacin
Description: Infants randomized to Escalating Dose group will receive indomethacin (0.2 mg/kg/dose) at 12 hr intervals for 2 doses, followed by indomethacin (0.3 mg/kg/dose) at 12 hr interval for 2 doses, then Indomethacin (0.4 mg/kg/dose) at 12 hr interval for 2 doses, increased to indomethacin (0.5 mg/kg/dose) at 12 hour interval for 2 doses and finally indomethacin 0.6 mg/kg/dose at 12 hourly interval for 2 doses.
Study: NCT01599585

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation
Description: Behavioral activation(BA)will be delivered in 8 weekly sessions via webcam for the in-home arm or face to face in the in-person arm. Behavioral activation attempts to help depressed individuals reengage in their lives through focused activation strategies.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Activation
Description: Behavioral activation(BA)will be delivered in 8 weekly sessions via webcam for the in-home arm or face to face in the in-person arm. Behavioral activation attempts to help depressed individuals reengage in their lives through focused activation strategies.
Study: NCT00923806

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PG13-CEA_TCR (Anti-CEA TCR PBL)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: 720,000 IU/kg intravenous over 15 minutes every 8 hours for up to 5 days
Study: NCT02192190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2951742
Description: Administered subcutaneously (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2951742
Description: Administered subcutaneously (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2951742
Description: Administered subcutaneously (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2951742
Description: Administered subcutaneously (SC)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo- oral
Description: Administered orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo- oral
Description: Administered orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo- oral
Description: Administered orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo- oral
Description: Administered orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo- oral
Description: Administered orally

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo - SC
Description: Administered SC
Study: NCT00448383

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: 40mg every other week
Study: NCT04302714

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hysteroscopic injection
Description: Hysteroscopic injection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical injection
Description: Cervical injection
Study: NCT05388513

Intervention type: PROCEDURE
Intervention: Surgical Resection
Description: Surgically treated patients included

Intervention type: PROCEDURE
Intervention: Surgical Resection
Description: Surgically treated patients included
Study: NCT03173287

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quantification of liver fibrosis
Description: Procedure MRI and liver biopsy
Study: NCT00289120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cola beverage
Description: Subjects will be given 500cc of Cola beverage twice daily to be ingested with breakfast and dinner for six days while on a metabolic diet.There will be a three weeks interval before crossover to the other treatment arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Deionized water
Description: Subjects will be given 500cc of deionized water to be ingested twice daily with breakfast and dinner for three weeks while on a metabolic diet. There will be a three weeks interval before crossover to the other treatment arm
Study: NCT04302038

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein
Description: Additional daily protein provided by potato protein.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: No additional dietary protein (outside of 0.8 g/kg/day as provided by diet)
Study: NCT02940808

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Caffeine (200mg)
Description: Oral consumption of capsule containing 200mg caffeine.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Caffeine (200mg)
Description: Oral consumption of capsule containing 200mg caffeine.

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Oral consumption of capsule containing a placebo substance.

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Oral consumption of capsule containing a placebo substance.
Study: NCT01144247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alloreactive CTL
Description: cellular immunotherapy with alloCTL
Study: NCT01507766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: early enteral nutrition
Description: The enteral nutrition was started within 48h after admission
Study: NCT03184987

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ACQ-7
Description: ACQ-7 will be used for the assessment of control status of asthma.
Study: NCT04817059

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Caseforge headcase
Description: We used a custom-fitted styrofoam head mold designed to reduce head motion during MRI scanning.
Study: NCT01507766

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Delayed enteral nutrition
Description: The enteral nutrition was started at the 8th day after admission
Study: NCT06304168

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study: NCT02192190

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo - SC
Description: Administered SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo - SC
Description: Administered SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo - SC
Description: Administered SC
Study: NCT04740840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levamlodipine
Description: According to the inclusion criteria of the trial, those who met the diagnosis of hypertension were randomly divided into the experimental group and the control group. The experimental group was treated with 2.5mg levamlodipine to lower blood pressure. Abdominal blood was emptying before the start of the trial and at the first and third month of medication.Data on CRP, TNF-α, IL-6, Lp-PLA2 and ATP were collected.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Amlodipine
Description: According to the inclusion criteria, patients who met the diagnosis of hypertension were randomly divided into the experimental group and the control group. The experimental group was given 5mg amlodipine to lower blood pressure. Fasting blood was collected before the trial and during the first and third months of treatment. CRP, TNF-α, IL-6, Lp-PLA2 and ATP data were collected.
Study: NCT00808535

Intervention type: PROCEDURE
Intervention: Cardiac Perfusion MRI w Vasomotor Stress
Description: All participants will undergo Cardiac Perfusion MRI with Vasomotor Stress. Vasomotor Stress will include both Cold Pressor Test and Adenosine Stress Test.

Intervention type: PROCEDURE
Intervention: Cardiac Perfusion MRI w Vasomotor Stress
Description: All participants will undergo Cardiac Perfusion MRI with Vasomotor Stress. Vasomotor Stress will include both Cold Pressor Test and Adenosine Stress Test.
Study: NCT01386242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant anti-tumor and anti-virus protein for injection
Description: Recombinant anti-tumor and anti-virus protein for injection,10μg,im,twice per week for first 2 weeks, followed by 20μg, im, twice per week after 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant anti-tumor and anti-virus protein for injection
Description: Recombinant anti-tumor and anti-virus protein for injection, 10μg/1mL,im,three times per week for first 2 weeks, followed by 20μg,im, three times per week after 2 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline Injection
Description: Saline Injection, 1mL, im,three times per week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant anti-tumor and anti-virus protein for injection
Description: Recombinant anti-tumor and anti-virus protein for injection, 10μg, im, three times per week for first week, followed by 20μg for two weeks, and followed by 30μg for a week, and followed a maintenance dose of 40μg, the frequency of administration is three times per week.
Study: NCT02770976

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Increasing and decreasing NAVA levels with 10-min intervals
Study: NCT03009838

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: oral tablets 2.5 mg

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ovarian drilling
Description: laparoscopic electrocauterization
Study: NCT03236012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A (Botox)
Description: Maximum dose up to 400 units given one time
Study: NCT00711490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: 20 μL (440 μg) of sirolimus were injected at baseline, Month 2, and every 2 months thereafter if re-treatment criteria were satisfied.
Study: NCT01333670

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prontosan wound irrigation solution
Description: * cleansing wound bed at change with Prontosan Wound Irrigation solution (syringe 20-30 ml, needle 19-20 G)~* positioning of sterile gauze dressing impregnated with Prontosan Wound Irrigation solution on the wound for 10 minutes~* dressing with Prontosan Wound Irrigation solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic solution (saline or lactated ringer)
Description: * cleansing wound bed at change with isotonic solution (syringe 20-30 ml, needle 19-20 G)~* positioning of sterile gauze dressing impregnated with isotonic solution on the wound for 10 minutes~* dressing with isotonic solution
Study: NCT03300843

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peptide loaded dendritic cell vaccine
Description: On days 0, 14 (+/- 5 days), 28 (+/- 5 days), and 42 (+/- 5 days). The vaccine will be administered as both an intravenous (IV) infusion and a subcutaneous (SQ) injection. The total dose will be divided equally between intravenous (IV) and SQ containing 1.0E7 to 8.0E7 cells per cycle depending upon the manufacturing yield.
Study: NCT02875691

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: green tea extract
Description: Patients are given daily dose of 1000mg aqueous green tea extract (of 6 grams of dried green tea leaf) in the form of 2 capsules( 500 mg) for three months.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Patients in placebo group receive daily dose of 1000 mg cellulose in the form of 2 capsules (500 mg) for three months
Study: NCT00311324

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Special Intervention
Study: NCT03749096

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Immunoglobulins, Human
Description: Immunoglobulins are fractionated blood products made from pooled human plasma.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Normal Saline
Study: NCT03352583

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein
Description: 40g calcium caseinate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein
Description: 40g calcium caseinate
Study: NCT00311324

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delayed Intervention
Study: NCT01006018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin + Pioglitazone PLACEBO
Description: Sitagliptin 100 mg tablet daily + Pioglitazone PLACEBO 15 mg capsule daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin + Pioglitazone
Description: Sitagliptin 100 mg tablet daily + Pioglitazone 15 mg capsule daily
Study: NCT02142725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LT-02
Description: four times per day
Study: NCT03451344

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Community-based rehabilitation group
Description: Participant in community-based rehabilitation group needs to visit their corresponding social worker for six months and accept illicit drug test every two months. Social worker will help their corresponding client to apply for social benefits accordingly, and provide counseling irregularly if necessary.
Study: NCT01012518

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard PCT
Description: The standard technique, performed without video guidance
Study: NCT02142725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LT-02
Description: two times per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: four times per day
Study: NCT01006018

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Sitagliptin placebo 100 mg tablet daily + Pioglitazone placebo 15 mg capsule daily
Study: NCT02782806

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Masimo Rad-67 Pulse Oximeter
Description: Noninvasive pulse oximeter
Study: NCT01449370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-117
Description: oral administration of TAK-117, daily and intermittent schedules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-117
Description: oral administration of TAK-117, daily and intermittent schedules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-117
Description: oral administration of TAK-117, daily and intermittent schedules.
Study: NCT02008435

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enriched GLB
Description: Habit formation techniques, namely if-then plans and their mental practice are being added to the standard Group Lifestyle Balance program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard GLB
Description: This arm is the standard Group Lifestyle Balance program